
Pharmacology Research & Perspectives (PR&P)
@prandp_journal
Open access pharmacology journal published by @ASPET, @BritPharmSoc & @WileyGlobal. No longer active on X.
ID: 892864146181689345
http://bpspubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2052-1707/ 02-08-2017 21:46:15
1,1K Tweet
2,2K Followers
355 Following

These findings support advancing to a phase 2 clinical trial for symptomatic cerebral cavernous malformation patients. π Read more in Pharmacology Research & Perspectives (PR&P): bpspubs.onlinelibrary.wiley.com/doi/10.1002/prβ¦ #ClinicalTrial #Pharmacology #MedicalResearch #Neurology #StrokePrevention #DrugDevelopment

Pharmacology Research & Perspectives (PR&P) is currently seeking submissions in the field of Pharmacology Education π. If your work is related to Pharmacology Education, please consider submitting to Pharmacology Research & Perspectives (PR&P) for your next publication. For more information visit: bpspubs.onlinelibrary.wiley.com/hub/journal/20β¦


The Pharmacology Research & Perspectives (PR&P) Special Issue is calling for manuscripts that provide a comprehensive overview of the therapeutic potential of psychedelic compounds for various neuropsychiatric disorders, as well as the prospects and challenges in this research area. π§΅(1/4)

Donβt miss this opportunity to submit your research to Pharmacology Research & Perspectives (PR&P)! Submission Deadline: September 30, 2024. More information: bpspubs.onlinelibrary.wiley.com/hub/journal/20β¦ #PsychedelicResearch #NeuropsychiatricDisorders #Pharmacology #DrugDevelopment #Therapeutics #ClinicalResearch π§΅(4/4)

Call for papers for Pharmacology Research & Perspectives (PR&P) that provide a comprehensive overview of the therapeutic potential of psychedelic compounds for various neuropsychiatric conditions, as well as the prospects and challenges in this exciting area. Learn more: ow.ly/QEHG50T27Vv




A recent study published in Pharmacology Research & Perspectives (PR&P) provides a comprehensive preclinical evaluation of ELP-004, an osteoclast inhibitor being developed to address bone erosion in arthritis patients. 𦴠π§΅(1/2)


π₯ Meet the 10 keynote speakers sharing their expert insights at #Pharmacology2024! Join us this December for 3 days of #DrugDiscovery, #PharmacologyEducation, #psychedelics, #cardiovascular medicine, #TransMedicine, & lots more. π Book your tickets now: miceconciergeme.com/pharmacology-2β¦




